|
Data demonstrates that IsoPSA Test is more specific to csPCA.
|
|
Greater Specificity for Better Biopsy Decisions
|
|
Because PSA testing is not specific to prostate cancer, it’s not always a reliable tool to determine which patients should be considered for prostate biopsies.
|
|
The IsoPSA Test is different: it advances prostate cancer risk assessment by analyzing the concentration and the structure of cancer-related PSA proteins.
|
|
The IsoPSA Test report also includes a total PSA result to eliminate the need to order a separate PSA test.
|
|
|
|
|
The IsoPSA Test provides improved specificity, with clinical data1 demonstrating that it is more than 2x specific for clinically significant disease compared to total PSA and %free PSA.
|
|
|
Explore Real-World Case Studies
|
|
Interested in learning more about the IsoPSA Test in clinical practice?
|
|
Visit isopsa.com to watch short case studies on how the IsoPSA Test can provide greater accuracy in identifying high-risk patients, enhance PI-RADS 1-3 interpretations, and support patient monitoring with its predictive value.
|
|
|
-
Klein, et al., Urol Oncol. 2022 Sep;40(9):408.e9-408.e18.
|
|
|
This material concerns the IsoPSA Test, a laboratory developed test (LDT) from Cleveland Diagnostics, Inc., which is performed by CLIA-certified laboratories qualified to conduct high-complexity clinical testing and is only intended for use consistent with applicable CLIA requirements. When offered as an LDT, the IsoPSA Test has not been cleared or approved by the U.S. Food and Drug Administration (FDA).
|
|
|
|
